“We underwent such digital transformation in the last few years, that we engage better with our physicians and patients than we ever have before,” said Andy Eeckhout, global head of customer relations management (CRM) and digital solutions at ADVANZ PHARMA, in relation to its collaboration with Veeva Systems.
At the Veeva Commercial Summit 2023, Eeckhout explained that the need for a digital revamp came alongside the pandemic as pharmaceutical companies faced a greater reliance on their digital platforms. However, he added that this has led to more long-term changes in ADVANZ’s operations.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe company began using Veeva Systems’ Commercial Cloud software four years ago, choosing to standardise all commercial operations with Veeva’s Commercial Cloud this year, as per a 20 June press release.
The rare disease company uses Veeva’s Commercial Cloud software to engage with key opinion leaders and customers, and has upcoming plans to leverage the system for the launch of a new health care provider (HCP) platform.
At the conference, Eeckhout discussed the pharma company’s use of Veeva’s Link Key People and Scientific Awareness data applications as part of its plans to launch a new HCP platform. ADVANZ has been preparing a new product website for HCPs, using the software, for the last ten months and has plans to launch the finished product in Q1 2024, he said. Eeckhout explained that the biotech has global sales in 90 countries, with an established presence in 20 of them, but the new platform will first be launched in the UK and Canada.
ADVANZ acquired Intercept Pharmaceuticals in 2022, giving it the exclusive rights to commercialise its primary biliary cholangitis drug Ocaliva (obeticholic acid) in all markets outside of the US. The rare disease company also recently announced the acquisition of the anti-androgen therapy Androcur (cyproterone acetate) from Bayer. In a 7 November press release, ADVANZ forecasted the completion of the deal to happen in Q1 2024. This followed previous 2023 deals to acquire the rights for Progynova (estradiol valerate) and Cyclo-Progynova (estradiol + levonorgestrel) in selected Latin American countries from Bayer, and a deal in which Kyowa Kirin gave ADVANZ the global rights to Tostran (testosterone).
